Semaglutide Single Dose Pen-Injector
Received Date: Jan 18, 2022 / Accepted Date: Feb 14, 2022 / Published Date: Feb 15, 2022
Abstract
Subcutaneous semaglutide, delivered by a single-dose pen-injector at a maintenance dose of 2.4mg once weekly, is approved in the USA for weight management in people with a body mass index (BMI) of 30 kg/m2 or higher, or with a BMI of 27 kg/m2 or higher and a minimum of one obesity-related co-morbidity. The semaglutide single-dose pen-injector could be a shield-activated auto-injector. Auto-injectors were at the start developed for emergency use however are used for chronic conditions for many years and for glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment for type 2 diabetes disease (T2D) since 2014. Shield activation entails the discharge of the injection by pushing the pen-injector against the patient's skin, as hostile activation via a button.
Keywords: Subcutaneous semaglutide, pen-injector
Citation: Yaser M (2022) Semaglutide Single Dose Pen-Injector. J Obes Metab 5: 114. Doi: 10.4172/jomb.1000114
Copyright: © 2022 Yaser M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Recommended Conferences
Dubai, UAE
天美传媒 Access Journals
Article Tools
Article Usage
- Total views: 1626
- [From(publication date): 0-2022 - Jan 11, 2025]
- Breakdown by view type
- HTML page views: 1281
- PDF downloads: 345
